Analysts Set BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Target Price at $25.00

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have received an average rating of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $25.00.

A number of brokerages recently weighed in on BBOT. HC Wainwright boosted their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Stifel Nicolaus began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 price objective for the company. Canaccord Genuity Group began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday. They set a “buy” rating and a $23.00 price objective for the company. Finally, Wall Street Zen downgraded shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday.

BridgeBio Oncology Therapeutics Stock Performance

Shares of BBOT stock opened at $8.51 on Monday. The firm has a market cap of $681.74 million, a price-to-earnings ratio of -5.60 and a beta of 0.22. BridgeBio Oncology Therapeutics has a 1-year low of $7.60 and a 1-year high of $14.87. The business’s fifty day moving average is $8.91.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. Equities research analysts predict that BridgeBio Oncology Therapeutics will post -2.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Institutional investors have recently modified their holdings of the business. CIBC Private Wealth Group LLC bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $107,000. Squarepoint Ops LLC bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $144,000. Quadrature Capital Ltd bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $162,000. Finally, BIT Capital GmbH acquired a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at about $313,000. Institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.